- This event has passed.
First in class Hit Finding, the In-Silico Way
February 25, 2021
A show case of our computational chemistry capabilities with emphasis on virtual screening and scaffold-hopping campaigns for first-in-class targets, demonstrated through scientific case studies. Application of latest Machine-learning algorithms to various end-points. Insights into Jubilant Biosys’ current ML model development, as a platform, for CardioTox, including individual classification models for hERG,Nav1.5 and Cav1.2 and many more similar models through the value chain.
Speakers
Rajendra Kristam
Principal Scientist, Computational Chemistry @Jubilant Biosys Limited
Rajendra has more than 17 years’ experience in Traditional and Computational Chemistry, beginning his career with Eli Lilly Research Centre, Windlesham, UK. Before joining us he worked with Aurigene Discovery Technologies and has been associated with Jubilant Biosys for the last 14 years. Rajendra holds MSc. Chemistry from University of Hyderabad and MSc. Chemoinformatics from University of Sheffield, Sheffield, UK. He has a MBA (Marketing) from Osmania University, Hyderabad, many research articles and patents to his credit. Rajendra heads the computational chemistry function at Jubilant Biosys and leads his team to support drug discovery projects. He has guided many virtual screening campaigns and scaffold-hopping efforts for hit-identification. He has been part of teams that delivered five clinical candidates and other targets too.
Saurabh Kapure
Vice President – Business Development (US & APAC) @Jubilant Biosys Limited
Saurabh has over 18 years of experience in corporate and international business development in pharmaceutical and drug discovery contract research organizations, marketing (product/brand management), strategic planning, alliance and process management. He has worked across various geographies like Europe, North America and Asia wherein he created and built businesses from scratch. His experience is spread across multiple Indian pharma cos including Torrent Pharma, Piramal Enterprises and Dr. Reddy’s Laboratories where he worked in various businesses around branded generics and Drug Discovery service providers including Aurigene Discovery, AMRI Global and Panacea Biotech both in managerial and leadership roles.
